SYS6043
As of the edition of 20 October 2026, SYS6043 is a drug known only by a code name: in active development; acts on CD276.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 5, 0 stopped early
- Disease areas
- Cancer; Hormones; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD276 | CD276 antigen | Q5ZPR3 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 3 | 0 | 3 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cspc | Lead sponsor of trials | 2024 to now |
| Conjupro Biotherapeutics | Lead sponsor of trials | 2026 to now |